



Your invitation to attend the Boehringer Ingelheim
and Eli Lilly ANZSN 2018 Breakfast Symposium

SGLT2 INHIBITORS CURRENT STATE OF PLAY

*Their increasing role in the management of
type 2 diabetes beyond glycaemic control*



KEYNOTE SPEAKER:

Prof Mark Thomas, MBBS (Syd), FRACP
Nephrologist, Royal Perth Hospital, WA

WHERE AND WHEN?

Venue: Meeting Room C3.4 + C3.5, International Convention Centre

Date: Tuesday 11th September 2018

Time: 7:00AM – 7:50AM

Breakfast will be provided. Numbers limited.

PLEASE REGISTER AT

<http://www.anzsnasm.com/industry-breakfasts>

OR

<https://cdesign.eventsair.com/anzsn2018/boehringerbreakfast/Site/Register>
by 5th September 2018



PROF MARK THOMAS, MBBS (SYD), FRACP

Prof Thomas trained at Sydney Hospital, RPA and Royal North Shore, then worked in a combined clinical-research position at Guy's Hospital in London for 3 years, before coming to Royal Perth Hospital as a staff nephrologist in 1988.

He has had an active interest in teaching general medicine and nephrology, which has included nurses, dental and medical students (both urban and rural), AMEC candidates, hospital junior staff, FRACP candidates and fellow nephrologists over the years, as well as many GP educational meetings.

He still works full-time at Royal Perth, with a tiny private practice in Kirkman House, and regular visiting nephrology service to remote areas of Western Australia, first to Kalgoorlie, and now Esperance and the isolated aboriginal community of Tjuntjuntjura in Spinifex country.

His clinical research interests include kidney disease in Aborigines, diabetic nephropathy, polycystic kidney disease, and the highly specialised problems of loin-pain/haematuria syndrome and Fabry's disease, where he runs the Statewide Service. He has published several book chapters, 60 peer-reviewed articles and 97 scientific abstracts.

Privacy statement: Personal information you provide to Eli Lilly Australia Pty Ltd ("ELAPL") and Boehringer Ingelheim Pty Ltd ("BIPL") will be used for purposes related to educational and promotional communication about our products and services and to respond to your questions or requests. If you do not provide the requested personal information to us, or if you use a pseudonym, we may not be able to fully and effectively respond to your questions or requests and we will not be able to keep you up-to-date with our educational and promotional information. BIPL and ELAPL may share the information with our related group companies and/or third party service providers (located outside of Australia including but not limited to New Zealand, Germany, USA and Japan) who we engage to assist us with this purpose and when we do, we will take reasonable measures to ensure that those third party service providers comply with the BIPL and the ELAPL Privacy Policies and are bound by the Australian Privacy Principles ("APPs") or similar privacy obligations. Our Privacy Policies contain information about how you can access and request the correction of your personal information. It also contains information about how you can make a complaint about a breach of the APPs and how we will deal with your complaint. You can contact ELAPL or our Privacy Officer at privacy_aus@lilly.com or BIPL or our Privacy Officer at PrivacyOfficer.SYD@boehringer-ingelheim.com. You can view the Eli Lilly Australia Privacy Policy at <https://www.lilly.com.au/en/privacy.aspx> and the Boehringer Ingelheim Privacy Policy at <http://www.boehringer-ingelheim.com.au/data-privacy>.

If you need to report an Adverse event for Boehringer Ingelheim products do not reply to this email but contact our Medical information on (02)8875 8601 or 1800 226 315. Boehringer Ingelheim Pty Limited is bound by the Australian Privacy Principles and adheres to these Principles. You can view our Privacy Policy at: <https://www.boehringer-ingelheim.com.au/data-privacy>. If you no longer wish to receive email communication from Boehringer Ingelheim.



Boehringer Ingelheim Pty Limited, ABN 52 000 452 308.
78 Waterloo Road, North Ryde, NSW 2113 Australia.
Copyright © 2018 BOEH0972. AU/DIA/00234. August 2018.



Eli Lilly Australia Pty Limited, ABN 39 000 233 992.
112 Wharf Road, West Ryde, NSW 2114 Australia.